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Statement of findings
The respiratory effects of dexmedetomidine were retrospectively examined in 33 postsurgical
patients involved in a randomised, placebo-controlled trial after extubation in the intensive care
unit (ICU). Morphine requirements were reduced by over 50% in patients receiving
dexmedetomidine. There were no differences in respiratory rates, oxygen saturations, arterial
pH and arterial partial carbon dioxide tension (PaCO2) between the groups. Interestingly the
arterial partial oxygen tension (PaO2):fractional inspired oxygen (FIO2) ratios were statistically
significantly higher in the dexmedetomidine group. Dexmedetomidine provides important
postsurgical analgesia and appears to have no clinically important adverse effects on
respiration in the surgical patient who requires intensive care.
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FIO2 = fractional inspired oxygen; ICU = intensive care unit; PaCO2 = arterial partial carbon dioxide tension; PaO2 = arterial partial oxygen tension.
Introduction: The a2-agonist dexmedetomidine is a new class
of sedative drug that is being investigated for use in ICU
settings. It is an effective agent for the management of sedation
and analgesia after cardiac, general, orthopaedic, head and
neck, oncological and vascular surgery in the ICU [1].
Cardiovascular stability was demonstrated, with significant
reductions in rate–pressure product during sedation and over
the extubation period.
Dexmedetomidine possesses several properties that may
additionally benefit those critically ill patients who require
sedation. In spontaneously breathing volunteers, intravenous
dexmedetomidine caused marked sedation with only mild
reductions in resting ventilation at higher doses [2].
Dexmedetomidine reduces the haemodynamic response to
intubation and extubation [3–5] and attenuates the stress
response to surgery [6], as a result of the a2-mediated
reduction in sympathetic tone. Therefore, it should be possible
to continue sedation with dexmedetomidine over the stressful
extubation period without concerns over respiratory depression,
while ensuring that haemodynamic stability is preserved.
The present study is a retrospective analysis of the respiratory
response to dexmedetomidine in 33 postsurgical patients (who
were involved in a randomized, double-blind, placebo-
controlled trial [1]) after extubation in the ICU.
Methods: Patients who participated in the present study were
admitted after surgery to our general or cardiothoracic ICUs,
and were expected to receive at least 6 h of postsurgical
sedation and artificial ventilation.
On arrival in the ICU after surgery, patients were randomized to
receive either dexmedetomidine or placebo (normal saline) with
rescue sedation and analgesia being provided, only if clinically
needed, with midazolam and morphine boluses, respectively.
Sedation was titrated to maintain a Ramsay Sedation Score [7]
of 3 or greater while the patients were intubated, and infusions of
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study drug were continued for a maximum of 6 h after extubation
to achieve a Ramsay Sedation Score of 2 or greater.
The patients were intubated and ventilated with oxygen-
enriched air to attain acceptable arterial blood gases, and
extubation occurred when clinically indicated. All patients
received supplemental oxygen after extubation, which was
delivered by a fixed performance device. Assessment of pain
was by direct communication with the patient.
Results are expressed as mean ± standard deviation unless
otherwise stated. Patient characteristics, operative details and
morphine usage were analyzed using the Mann–Whitney U-
test. Statistical differences for respiratory measurements
between the two groups were determined using analysis of
variance for repeated measures, with the Bonferroni test for
post hoc comparisons.
Results: Of the 40 patients who participated in the study,
seven patients could not be included in the analysis of
respiratory function because they did not receive a study drug
infusion after extubation. Consequently, data from 33 patients
are used in the analysis of respiratory function; 16 received
dexmedetomidine and 17 placebo. Inadequate arterial blood
gas analysis was available in five patients (two from the
dexmedetomidine group, and three from the placebo group).
There were no significant differences in patient characteristics
and operative details between the groups.
Requirements for morphine were reduced by more than 50% in
patients receiving dexmedetomidine when compared with
placebo after extubation (0.003 ± 0.004 vs 0.008 ± 0.006 mg/kg
per h; P= 0.040).
There were no statistically significant differences between
placebo and dexmedetomidine for oxygen saturations measured
by pulse oximetry (P = 0.26), respiratory rate (P = 0.16; Fig. 1),
arterial pH (P = 0.77) and PaCO2 (P = 0.75; Fig. 2) for the 6 h
after extubation.
The dexmedetomidine group showed significantly higher
PaO2:FIO2 ratios throughout the 6-h intubation (P = 0.036) and
extubation (P = 0.037) periods (Fig. 3). There were no adverse
respiratory events seen in either the dexmedetomidine or
placebo group.
Discussion: Lack of respiratory depression in patients sedated
with a2-adrenoceptor agonists was first reported by Maxwell
[8] in a study investigating the respiratory effects of clonidine.
However, more recent data suggests that clonidine may cause
mild respiratory depression in humans [9], and a2-
adrenoceptor agonists are well known to produce profound
intraoperative hypoxaemia in sheep [10,11]. The effects of
dexmedetomidine on other ventilation parameters also appear
to be species specific [12].
Belleville et al [2] investigated the ventilatory effects of a 2-min
intravenous infusion of dexmedetomidine on human volunteers.
According to those investigators, minute ventilation and arterial
PaCO2 were mildly decreased and increased, respectively.
There was a rightward shift and depression of the hypercapnic
response with infusions of 1.0 and 2.0 mg/kg.
Previous studies that investigated the respiratory effects of
dexmedetomidine have only been performed in healthy human
volunteers, who have received either single intramuscular
injections or short (= 10 min) intravenous infusions of
dexmedetomidine. It is therefore reassuring that no deleterious
clinical effects on respiration and gas exchange were seen in
the patients we studied, who were receiving long-term infusions.
However, there are important limitations to the present results.
No dose/response curve for dexmedetomidine can be
formulated from the data, and further investigation is probably
ethically difficult to achieve in the spontaneously ventilating
intensive care patient. We also have no data on the ventilatory
responses to hypercapnia and hypoxia, which would also be
difficult to examine practically and ethically. The placebo group
Figure 1
Respiratory rate for the 6-h periods before and after extubation. (l)
Dexmedetomidine; (¡) placebo. Values are expressed as 
mean ± standard deviation.
Figure 2
PaCO2 (PCO2) for the 6-h periods before and after extubation, and
baseline values (B) on admission to ICU immediately after surgery. 
(l) Dexmedetomidine; (¡) placebo. Values are expressed as 
mean ± standard deviation.Critical Care    Vol 4 No 5 Venn et al
received more than twice as much morphine as patients
receiving dexmedetomidine infusions after extubation, but there
were no differences in respiratory rate or PaCO2 between the
groups. We can not therefore determine from this study
whether dexmedetomidine has any benefits over morphine from
a respiratory perspective.
There were no differences in oxygen saturations between the
groups because the administered oxygen concentration was
adjusted to maintain satisfactory gas exchange. Interestingly,
however, there were statistically significant higher PaO2:FIO2
ratios in the dexmedetomidine group. This ratio allows for the
variation in administered oxygen to patients during the study
period, and gives some clinical indication of alveolar gas
exchange. However, this variable was not a primary outcome
variable for the present study, and may represent a type 1 error,
although  post hoc analysis reveals that the data have 80%
power to detect a significant difference (a value 0.05). Further
studies are obviously required.
Sedation continued over the extubation period, has been
shown to reduce haemodynamic disturbances and myocardial
ischaemia [13]. We have previously shown [1] that
dexmedetomidine provides cardiovascular stability, with a
reduction in rate–pressure product over the extubation period.
A sedative agent that has analgesic properties, minimal effects
on respiration and offers ischaemia protection would have
enormous potential in the ICU. Dexmedetomidine may fulfill all
of these roles, but at present we can only conclude that
dexmedetomidine has no deleterious clinical effects on
respiration when used in doses that are sufficient to provide
adequate sedation and effective analgesia in the surgical
population requiring intensive care.
Introduction
The a2-agonist dexmedetomidine is a new class of seda-
tive drug that is being investigated in ICU settings. It is an
effective agent for the management of sedation and anal-
gesia after cardiac, general, orthopaedic, head and neck,
oncological and vascular surgery in the ICU [1]. Cardio-
vascular stability was demonstrated with significant reduc-
tions in rate–pressure product during sedation and over
the extubation period.
Dexmedetomidine possesses several properties that may
additionally benefit those critically ill patients who require
sedation. In spontaneously breathing volunteers intravenous
dexmedetomidine caused marked sedation, with only mild
reductions in resting ventilation at higher doses [2]. In
animal studies dexmedetomidine did not appear to potenti-
ate the respiratory depression of opioids when used in com-
bination [14], and these results were reproduced with
another a2-agonist, clonidine, in human volunteers [15].
Dexmedetomidine reduces the haemodynamic response to
intubation and extubation [3–5] and attenuates the stress
response to surgery [6], as a result of the a2-mediated
reduction in sympathetic tone. It should therefore be possi-
ble to continue sedation with dexmedetomidine over the
stressful extubation period without concerns over respira-
tory depression, while ensuring that haemodynamic stability
is preserved. After extubation dexmedetomidine can con-
tinue to provide analgesia to the postoperative patient, thus
reducing the need for opioids and their side effects.
We retrospectively analyzed the respiratory response to
dexmedetomidine in postsurgical patients after extubation
in the ICU. These patients were involved in a multicentre
trial conducted to examine the safety and efficacy of
dexmedetomidine in the ICU [1], and only data from our
centre has been included.
Materials and methods
Forty patients from our hospital, who had been recruited
into a multicentre, randomized, double blind, placebo-con-
trolled trial, were retrospectively analyzed. Patients partici-
pating in this study were admitted after surgery to our
general or cardiothoracic ICUs, and were expected to
receive at least 6 h of postsurgical sedation and artificial
ventilation. Exclusion criteria included the following:
serious central nervous system trauma; requirement for an
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Figure 3
PaO2:FIO2 ratio for the 6-h periods before and after extubation, and
baseline values (B) on admission to ICU immediately after surgery. 
(l) Dexmedetomidine; (¡) placebo. Values are expressed as 
mean ± standard deviation.http://ccforum.com/content/4/5/302
infusion of a neuromuscular blocking agent; any con-
traindications or allergy to any of the trial drugs; gross
obesity (over 50% above ideal body weight); prior enroll-
ment in a trial with any experimental drug during the past
30 days; and uncontrolled diabetes.
Anaesthetic technique was not controlled during surgery,
although benzodiazepines were not allowed as the sole
anaesthetic agent.
On arrival in the ICU after surgery, patients were random-
ized to receive either dexmedetomidine or placebo (normal
saline), with rescue sedation and analgesia being provided,
only if clinically needed, with midazolam and morphine
boluses, respectively. A detailed description of the methods
has previously been reported [1]. Essentially, all patients
received a loading dose of study drug within 1 h of arriving
in the ICU, followed by a variable infusion, to maintain a
Ramsay Sedation Score [7] of 3 or greater while intubated.
After extubation, infusions of study drug were continued for
a maximum of 6 h to target a Ramsay Sedation Score of 2
or greater. In this latter period, morphine and paracetamol
boluses could be used for analgesia. Patients were only
allowed the study drug infusion for a maximum of 24 h, and
were converted to the usual sedation regimen of the unit if
there was a continued need for sedation.
The patients were intubated and ventilated with oxygen-
enriched air to attain acceptable arterial blood gases, and
could receive any other therapeutic interventions that were
deemed necessary by the resident ICU staff. Extubation
occurred when it was clinically indicated. All patients
received supplemental oxygen after extubation, which was
delivered by a fixed performance device. Assessment of
pain was by direct communication with the patient.
Heart rate, blood pressure, central venous pressure, pulse
oximetry and respiratory rate were monitored continuously
and recorded hourly. Arterial blood gases were recorded
at 2-h intervals over the extubation period.
Statistical analysis
Results are expressed as mean ± standard deviation
unless otherwise stated. Patient characteristics, operative
details and morphine usage were analyzed using the
Mann–Whitney U-test. Statistical differences for respiratory
measurements between the two groups were determined
using analysis of variance for repeated measures. Post hoc
comparisons were made using the Bonferroni test to deter-
mine differences among groups at individual time points, as
well as differences over time within individual groups.
Power analysis for the numbers studied at our centre
would be expected to show a difference of 25% in respi-
ratory rate and PaCO2 between the two groups (a value
0.05, b value 0.8).
Results
Of the 40 patients who participated in the study, seven
could not be included in the analysis of respiratory func-
tion because they did not receive a study drug infusion
after extubation. One patient required ventilation for longer
than 24 h, and five patients were withdrawn from the study
before extubation: two patients returned to the operating
theatre because of bleeding; one had residual neuromus-
cular blockade; one had bradycardia with hypotension
requiring a pacemaker; and one was withdrawn at the sur-
geon’s request because of operative complications. A
further patient had the study drug discontinued in error
before extubation.
Consequently, data from 33 patients were used in the
analysis of respiratory function, and 16 of these patients
received dexmedetomidine and 17 received placebo.
Inadequate arterial blood gas analysis was available in five
patients (two from the dexmedetomidine group, three from
the placebo group) because of problems with sampling
from the arterial cannula. There were no significant differ-
ences with respect to type of operation, age, sex, weight,
height, intubation time, weaning time from the ventilator
and study drug infusion time (Table 1).
Mean infusion rates for dexmedetomidine before extuba-
tion and during the extubated period were 0.42 ± 0.18
and 0.17 ± 0.13 mg/kg per h, respectively, and there were
no differences in the distribution of Ramsay Sedation
Scores between the placebo and dexmedetomidine
groups. Requirements for morphine were reduced by half
in patients receiving dexmedetomidine while intubated
when compared with placebo (0.011 ± 0.02 versus
0.022 ± 0.02 mg/kg per h; P = 0.024), and this morphine-
sparing effect of dexmedetomidine was even more pro-
nounced during the extubation period (0.003 ± 0.004
versus 0.008 ± 0.006 mg/kg per h; P = 0.040; Fig. 4). In
the dexmedetomidine group 50% (eight out of 16)
patients required no morphine at all after extubation, com-
pared with 24% (four out of 17) in the placebo group.
There were no statistically significant differences between
the placebo and dexmedetomidine groups for oxygen sat-
urations measured by pulse oximetry (P = 0.26) and respi-
ratory rate (P = 0.16) for the 6 h following extubation
(Figs 1 and 5). There were no differences in arterial pH
(P = 0.77) and PaCO2 (P = 0.75) measurements between
the groups, and within the dexmedetomidine group, over
the same 6-h period (Figs 2 and 6).
Because all patients received oxygen therapy throughout
the study period, the PaO2:FIO2 ratio was used to
compare oxygenation. There were significant differences
in the PaO2:FIO2 ratios for the 6-h extubation period
(P = 0.037) and for the 6-h period while intubated before
extubation between the two groups (P = 0.036). Thedexmedetomidine group showed significantly higher
PaO2:FIO2 ratios throughout these periods (Fig. 3). There
were no adverse respiratory events seen in either the
dexmedetomidine or placebo group.
Discussion
The present results show that dexmedetomidine appears
to have no clinically important adverse effects on respira-
tory rate and gas exchange when used in spontaneously
breathing ICU patients after surgery.
Lack of respiratory depression in patients sedated with a2-
adrenoceptor agonists was first reported by Maxwell [8] in
a study conducted to investigate the respiratory effects of
clonidine. However more recent data [9] suggest that
clonidine may cause mild respiratory depression in
humans. Furthermore, a2-adrenoceptor agonists have
been reported to produce profound intraoperative hypox-
aemia, which is species specific and is particularly seen in
sheep [10,11].
The effects of dexmedetomidine on other ventilation para-
meters similarly appear to be species specific. Thus, in
dogs dexmedetomidine causes an increase in minute ven-
tilation, without any change in arterial blood gases, but
causes a decreased response to inhaled carbon dioxide
[12]. However, in New Zealand white rabbits dexmedeto-
midine caused marked and dose-dependent reductions in
respiratory rate and PaO2 and significant rises in arterial
PaCO2, which persisted 60 min after cessation of the
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Table 1
Patient characteristics and operative details for the dexmedetomidine and placebo groups
Dexmedetomidine Placebo
Type of surgery (cardiac/general) 9/7 10/7
APACHE II score for general surgical patients (median [interquartile range]) 10 (5) 10 (2)
Parsonnett score for cardiac surgery patients (median [interquartile range]) 10 (6) 13 (7)
Age (years) 63 ± 15 63 ± 15
Sex (male/female) 12/4 11/6
Wean-extubation time (h) 2.6 ± 2.7 2.4 ± 2.5
Intubation time (h) 10.5 ± 4.5 9.0 ± 4.4
Total infusion (intubation + extubation; h) 17.5 ± 3.7 15.1 ± 4
Values are expressed as mean ± standard deviation or as numbers, unless otherwise stated. APACHE, Acute Physiology and Chronic Health
Evaluation.
Figure 4
Requirements for rescue analgesia with morphine during the
extubation period for patients receiving dexmedetomidine and placebo.
Values are medians; boxes indicate 25–75th percentiles and bars
indicate the range.
Figure 5
Oxygen saturation measured by pulse oximetry for the 6-h periods
before and after extubation. (l) Dexmedetomidine; (¡) placebo.
Values are expressed as mean ± standard deviation.dexmedetomidine infusion [15]. Idazoxan, a specific a2-
adrenoceptor antagonist, reversed the effects on sedation
and PaCO2.
Belleville et al [2] investigated the ventilatory effects of a
2-min intravenous infusion of dexmedetomidine at four
dose levels (maximum 2.0 mg/kg) in human volunteers.
Immediately after the maximum infusion of 2.0 mg/kg, irreg-
ular breathing patterns were noticed with short periods of
apnoea, although there were no episodes of significant
arterial oxygen desaturation to below 90%. According to
those authors, minute ventilation and arterial PaCO2 were
mildly decreased and increased, respectively, in relation to
the depth of sedation as a result of dexmedetomidine infu-
sions of 1.0 and 2.0 mg/kg. The reduction in minute venti-
lation was predominantly a result of a reduction in tidal
volume, although there was a small but nonsignificant
reduction in respiratory rate. There was a rightward shift
and depression of the hypercapnic response at these infu-
sion doses.
The mechanisms for these changes in ventilation are
unknown, but it is possible that they are a result of central
respiratory depression, given the distribution of a2-adreno-
ceptors in the brainstem [16]. However, the effects of
dexmedetomidine on human respiration are much less
marked than those of opioids and other intravenous and
volatile anaesthetic agents, and appear to be similar in
order of magnitude to those seen in the heavy sleep state.
Previous studies that investigated the respiratory effects
of dexmedetomidine have only been performed in healthy
human volunteers, who have received either single intra-
muscular injections or short (£10 min) intravenous infu-
sions of dexmedetomidine. It is therefore reassuring that
no deleterious clinical effects on respiration and gas
exchange were seen in our patients, who received long-
term infusions of dexmedetomidine.
However, there are important limitations to the present
results. In this study patients were sedated to a Ramsay
Sedation Score of 2 or greater after extubation, and so we
do not have respiratory function data on patients who
were more heavily sedated. Consequently, no clear
dose/response curve for dexmedetomidine can be formu-
lated, and further investigation is probably ethically difficult
to achieve in the spontaneously ventilating intensive care
patient. We also have no data on the ventilatory responses
to hypercapnia and hypoxia, which have been studied in
healthy volunteers, but again this would be difficult to
examine practically and ethically. The placebo group
received over twice as much morphine as did patients
who received dexmedetomidine infusions after extubation,
but there were no differences in respiratory rate or PaCO2
between the groups. We can not therefore determine from
the present study whether dexmedetomidine has any ben-
efits over morphine from a respiratory perspective.
There were no differences in oxygen saturations between
the groups, because the administered oxygen concentra-
tion was adjusted to maintain satisfactory gas exchange.
Interestingly, however, there were statistically significant
higher PaO2:FIO2 ratios in the dexmedetomidine group
after extubation and for the intubated period before extu-
bation. This ratio allows for the variation in administered
oxygen to patients during the study period, and gives us
some clinical indication of alveolar gas exchange.
However, this variable was not a primary outcome variable
for the study, and may represent a type 1 error, although
post hoc analysis revealed that the present data have 80%
power to detect a significant difference (a value 0.05).
While intubated, ventilation was adjusted to maintain satis-
factory gas exchange, and so mode of ventilation, tidal
volumes, positive end-expiratory pressure, etc, may not
have been equivalent between the groups, and this may
explain some of the differences. However, this can not
explain the improvements in gas exchange seen during the
extubation period, when the only ventilation variable was
the FIO2. Circulatory variables were not measured (oxygen
uptake, cardiac output and mixed venous oxygen content),
and again these may have been responsible for some of
the differences in PaO2:FIO2 ratio that were observed.
Further investigations are required to exclude a type 1
error and to elucidate the exact mechanism for these
effects if this phenomenon is reproduced in other studies.
a2-Adrenergic-induced hypoxaemia, which is seen particu-
larly in sheep, does not appear to occur, and a great deal
is still to be learned about organ-specific and species-spe-
cific distribution and density of a2-adrenoceptors, and the
individual specificity of a2-adrenoceptor agonists.
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Figure 6
Arterial pH for the 6 hour periods before and after extubation, and
baseline values (B) on admission to ICU immediately after surgery. 
(l) Dexmedetomidine; (¡) placebo. Values are expressed as 
mean ± standard deviation.The clinical benefits of a sedative and analgesic agent in
the ICU that has only mild respiratory depressant effects
are immediately apparent. Sedation continued over the
extubation period has been shown [13] to reduce haemo-
dynamic disturbances and myocardial ischaemia, but is
currently rarely performed because of the known negative
effects on respiration from the sedative agents that are
currently available. We have previously shown that
dexmedetomidine provides cardiovascular stability, with a
reduction in rate–pressure product over the extubation
period, and so might protect against ischaemia, indepen-
dently of its sedative properties, as a consequence of its
a2-agonist activity [1]. A sedative agent that has analgesic
properties, minimal effects on respiration and may offer
ischaemia protection would also have enormous potential
outside the ICU. Dexmedetomidine may fulfill all of these
roles, but at present we can only conclude that
dexmedetomidine has no deleterious clinical effects on
respiration when used in doses that provide adequate
sedation and effective analgesia in the surgical population
requiring intensive care.
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